Baidu
map

Diabetic Med:高血压患者治疗时HDL低预示新发糖尿病风险更高

2013-04-29 Diabetic Med 糖尿病在线

  既往研究表明,基线高密度脂蛋白胆固醇(HDL-C)水平较低的高血压患者发生糖尿病的风险增加。美国纽约威尔康奈尔医学院Peter M. Okin等开展的一项研究表明,与基线HDL-C水平较低者相比,治疗期间HDL-C水平仍较低者新发糖尿病的风险更大。(Diabetic Med. 2013年4月16日在线版)   该研究纳入7485例无糖尿病史的高血压患者

  既往研究表明,基线高密度脂蛋白胆固醇(HDL-C)水平较低的高血压患者发生糖尿病的风险增加。美国纽约威尔康奈尔医学院Peter M. Okin等开展的一项研究表明,与基线HDL-C水平较低者相比,治疗期间HDL-C水平仍较低者新发糖尿病的风险更大。(Diabetic Med. 2013年4月16日在线版)

  该研究纳入7485例无糖尿病史的高血压患者,平均随访4.7年。520例患者发生糖尿病。单变量Cox分析表明,与HDL-C水平处于最高四分位(>1.78 mmol/L)者相比,基线和治疗期间HDL-C水平处于最低四分位(<1.21 mmol/L)者新发糖尿病的风险分别增加4倍和8倍以上,其余患者发生糖尿病的风险相对较低。多因素Cox分析显示,治疗期间HDL-C水平处于最低四分位者罹患糖尿病的风险约为HDL-C水平最高者的9倍(HR=8.7),而基线HDL-C水平<1.21 mmol/L者发生糖尿病的风险低得多(HR=3.9)。

糖尿病相关的拓展阅读:


In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: The LIFE Study
Aims
Although hypertensive patients with low baseline HDL cholesterol levels have a higher incidence of diabetes mellitus, whether changing levels of HDL over time are more strongly related to the risk of new diabetes in hypertensive patients has not been examined.
Methods
Incident diabetes mellitus was examined in relation to baseline and in-treatment HDL levels in 7485 hypertensive patients with no history of diabetes randomly assigned to losartan- or atenolol-based treatment.
Results
During 4.7 ± 1.2 years follow-up, 520 patients (6.9%) developed new diabetes. In univariate Cox analyses, compared with the highest quartile of HDL levels (> 1.78 mmol/l), baseline and in-treatment HDL in the lowest quartile (< 1.21 mmol/l) identified patients with > 5-fold and > 9 fold higher risks of new diabetes, respectively; patients with baseline or in-treatment HDL in the 2nd and 3rd quartiles had intermediate risk of diabetes. In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8.7, 95% CI 5.0–15.2), whereas the risk of new diabetes was significantly attenuated for baseline HDL < 1.21 mmol/l (hazard ratio 3.9, 95% CI 2.8–5.4).
Conclusions
Lower in-treatment HDL is more strongly associated with increased risk of new diabetes than baseline HDL level.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970461, encodeId=63fc19e046155, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 26 23:56:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636654, encodeId=53aa163665416, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jun 02 21:56:00 CST 2013, time=2013-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759269, encodeId=87e61e59269af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 10 15:56:00 CST 2013, time=2013-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316396, encodeId=8c7f13163960d, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448116, encodeId=e7ec144811626, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605930, encodeId=450816059302b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1970461, encodeId=63fc19e046155, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 26 23:56:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636654, encodeId=53aa163665416, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jun 02 21:56:00 CST 2013, time=2013-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759269, encodeId=87e61e59269af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 10 15:56:00 CST 2013, time=2013-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316396, encodeId=8c7f13163960d, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448116, encodeId=e7ec144811626, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605930, encodeId=450816059302b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1970461, encodeId=63fc19e046155, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 26 23:56:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636654, encodeId=53aa163665416, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jun 02 21:56:00 CST 2013, time=2013-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759269, encodeId=87e61e59269af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 10 15:56:00 CST 2013, time=2013-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316396, encodeId=8c7f13163960d, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448116, encodeId=e7ec144811626, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605930, encodeId=450816059302b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1970461, encodeId=63fc19e046155, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 26 23:56:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636654, encodeId=53aa163665416, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jun 02 21:56:00 CST 2013, time=2013-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759269, encodeId=87e61e59269af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 10 15:56:00 CST 2013, time=2013-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316396, encodeId=8c7f13163960d, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448116, encodeId=e7ec144811626, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605930, encodeId=450816059302b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1970461, encodeId=63fc19e046155, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 26 23:56:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636654, encodeId=53aa163665416, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jun 02 21:56:00 CST 2013, time=2013-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759269, encodeId=87e61e59269af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 10 15:56:00 CST 2013, time=2013-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316396, encodeId=8c7f13163960d, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448116, encodeId=e7ec144811626, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605930, encodeId=450816059302b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1970461, encodeId=63fc19e046155, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 26 23:56:00 CST 2014, time=2014-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636654, encodeId=53aa163665416, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jun 02 21:56:00 CST 2013, time=2013-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759269, encodeId=87e61e59269af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 10 15:56:00 CST 2013, time=2013-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316396, encodeId=8c7f13163960d, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448116, encodeId=e7ec144811626, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605930, encodeId=450816059302b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]

相关资讯

BMJ:高钾摄入降低高血压患者的血压

血压升高和高血压病是心血管疾病,特别是冠心病、中风、心衰以及肾衰的主要危险因素。钾是维持总体液量、酸和电解质平衡,以及正常细胞功能需要的必需营养素。为了填补钾摄入和健康的知识空白,来自世界卫生组织健康发展营养部的Nancy J Aburto研究院及其团队进行了一项系统性的文献回顾和荟萃分析,该研究发现钾摄入增加降低高血压患者的血压,较高的钾摄入与卒中风险的降低相关。该研究结果发表在2013年4月5

摄钠过量,幼儿也患高血压

  美国心脏协会(American Heart Association,AHA)在3月21日新奥尔良召开的2013年美国心脏协会的流行病学和预防/营养、身体活动和代谢科学会议上表明,近75%的幼儿包装食品和美味小吃对刚学步的小儿来说,含钠量偏高。   由于幼儿发育尚未健全,肾脏功能还未成熟,无法及时代谢血液中过量的钠,导致水钠潴留,严重可致肾功能损害,继发高血压,还有可能增加心脏的负担。摄

Hypertension:靶向交感神经消融可降低遗传盐敏感性高血压

交感神经系统在高血压人群和Dahl盐敏感高血压大鼠模型起着一定作用,但其中涉及哪些交感神经并不清楚。为阐述这一问题,美国明尼苏达大学的研究人员对肾脏和内脏交感神经在Dahl高血压小鼠模型中的作用进行验证,他们将实验模型分为假手术组(n=10),靶向肾交感神经消融组(肾脏去神经支配组, n=11),内脏神经消融组(腹腔神经节去除组,n=11),肾脏神经和腹腔神经联合消融组(n=11)。给予0.4%氯

EHJ:ESC支持肾脏去神经化能用于难治性高血压治疗

     日前,欧洲心脏病学会(ESC)发布了一份共识声明,称经导管肾脏去交感神经术(catheter-based renal denervation),也称经导管肾交感神经消融术,可作为高血压治疗的一种备选治疗策略,适用于在生活方式调整和药物治疗后未达到降压目标的耐药性高血压患者。     本声明在线发表于2013

高血压的控制:争鸣仍未息

    高血压的研究已很多年,但在很多领域仍有许多东西是未知的。他们认为一些看似简单的问题缺乏证据,比如不同人群降压的理想数值,并且认为应该为此进行许多新的实验。与此同时,由于治疗高血压的重担更多的落在了全科医生及家庭医生的肩上,指南也应为他们提供最好的指导。     意大利蒙扎Milan Bicocca大学Giusepp

Hypertension:心血管危险因素或可诱发胎盘早剥

  荷兰和英国一项联合研究表明,确定性心血管危险因素可诱发胎盘早剥以及后期早发心血管疾病形成。论文4月8在线发表于《高血压》(Hypertension)。   此项研究共纳入75例伴有胎盘早剥病史的女性以及79例无事件妊娠对照女性,并在产后6至9个月比较了常见心血管危险因素的存在情况。依据并发高血压病存在与否对数据加以分成,并对潜在混淆因素进行更深入校正。   结果显示,与无事件妊娠的对照者相

Baidu
map
Baidu
map
Baidu
map